期刊文献+

朱红膏促进皮肤溃疡愈合的安全性研究 被引量:17

Safety Study on Zhuhong Ointment of Promoting Dermal Ulcer Healing
下载PDF
导出
摘要 目的研究朱红膏促进皮肤溃疡愈合的安全性,为临床用药提供依据。方法 SD雄性大鼠66只随机分为皮肤破损组、溃疡模型组、凡士林基质组及朱红膏高(38.08 mg/kg)、中(19.04 mg/kg)、低(9.52 mg/kg)剂量组。皮肤破损组仅以刀片刮伤大鼠皮肤;溃疡模型组选择皮肤缺损+细菌感染+埋置异物法造模;朱红膏和凡士林基质组以纱条方式在大鼠造模创面上贴敷给药14 d,每日保证给药时间4 h,观察尿β-N-乙酰氨基葡萄糖苷酶(NAG)活性、尿视黄醇结合蛋白(RBP)含量及肾脏组织病理改变。结果与溃疡模型组比较,朱红膏各剂量组、凡士林基质组及皮肤破损组尿NAG活性未见明显差异(P>0.05),尿RBP含量显著升高(P<0.05,P<0.01),肾脏组织病理检查结果示,随着用药剂量的增加,肾脏组织病变有加重趋势,与皮肤破损组比较,朱红膏高剂量组有较明显病变(P<0.05),与溃疡模型组比较,朱红膏各剂量组、凡士林基质组及皮肤破损组肾脏病变未见明显差异(P>0.05)。结论朱红膏中剂量用药2周可认为基本安全,朱红膏高剂量用药2周有可能引起肾脏损伤。 Objective To study the safety of Zhuhong Ointment in promoting dermal ulcer healing and to provide the basis for clinical administration.Method Sixty-six male SD rats were randomly divided into the damaged skin group,ulcer model group,vaseline control group,and high-,middle-,low-dose Zhuhong ointment groups.Each group was treated by corresponding methods for 14 d.NAG and RBP contents in urine were taken as monitoring indexes,and the pathological morphology changes of kidney were observed. Results There was no significant difference in NAG content between Zhuhong Ointment groups and ulcer model group(P〉0.05).The RBP content in ulcer model group was remarkably lower than other groups(P〈 0.05,P〈0.01).Kidney pathological changes of high-dose Zhuhong ointment group were significantly increased than that of damaged skin group(P〈0.05).Conclusion Middle dose of Zhuhong Ointment used for 2 weeks can be regarded as safe.High dose of Zhuhong Ointment used for 2 weeks may cause renal injury.
出处 《中国中医药信息杂志》 CAS CSCD 2011年第6期47-49,共3页 Chinese Journal of Information on Traditional Chinese Medicine
基金 国家科技支撑计划(2008BAI53B085)
关键词 朱红膏 皮肤溃疡 肾毒性 大鼠 Zhuhong Ointment; dermal ulcer; nephrotoxicity; rats
  • 相关文献

参考文献3

二级参考文献13

  • 1陈荣明.小鼠皮肤创面外用红升丹及其制剂对肾脏的毒性和机理初探[J].南京中医药大学学报,1995,11(2):73-75. 被引量:26
  • 2Tomlinson PA. Low molecular weight proteins in children with renal disease. Pediatr Nephrol, 1992, 6:565-571 .
  • 3Bazzi C, Petrini C, Rizza V,et al. Urinary N-acetyl-β-glucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis. Nephrol Dial Transplant, 2002, 17:1890-1896.
  • 4ernard AM, Vyskocil AA, Mahieu P, et al. Assessment of urinary retinal-binding protein as an index of proximal tubular injury. Clin Chem, 1987, 33:775-779 .
  • 5Bosomworth MP, Aparicio SR, Hay AWM. Urine N-acetyl-b-Dglucosaminidase-a marker of tubular damage? Nephrol Dial Transplant, 1999, 14: 620-626.
  • 6Hultberg B, Ravnskov U. The excretion of N-acetyl-b-Dglucosaminidase in glomerulonephritis. Clin Nephrol, 1981, 15: 33.
  • 7Perez-Blanco FJ, Garbin-Fuentes I, Perez-Chica G,et al. Urinary activity of N-acetyl-b-D-glucosaminidase and progression of retinopathy in non-insulin-dependent diabetes mellitus. Clin Nephrol, 1997, 48: 388-389.
  • 8Rustom R, Castigan M, Shenkin A,et al. Proteinuria and renal tubular damage: urinary N-acetyl-b-D-glucosaminidase and isoenzymes in dissimilar renal disease. Am J Nephrol, 1998, 18: 179-185.
  • 9Rask L, Anundi H, Bohme J,et al. The retinal-binding protein. Scand J Clin Lab Invest, 1980, 40:45.
  • 10Price RG. The role of NAG (N-acetyl-b-D-glucosaminidase) in the diagnosis of kidney disease including the monitoring of nephrotoxicity. Clin Nephrol, 1992, 38 [Suppl]: 14-19.

共引文献84

同被引文献158

引证文献17

二级引证文献116

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部